Seattle Genetics and Astellas' new drug for relapsed bladder cancer - Padcev - could move up the treatment pathway with help from Merck & Co's Keytruda. An ongoing phase 1b/2 trial of recently ...

Astellas and Seagen's Padcev is on course to move further up the treatment pathway in bladder cancer, thanks to a positive readout in the EV-103 clinical trial. The latest results come from cohort ...

T he FDA has approved a combination therapy of Pfizer (NYSE:PFE) and Astellas’ (OTCPK:ALPMY) (OTCPK:ALPMF) drug Padcev and Merck’s (NYSE:MRK) Keytruda for the treatment of locally advanced or ...